158 citations
,
February 2000 in “Archives of dermatology”
This study reports that some patients with androgenetic alopecia may also exhibit clinical and histological features of inflammation and fibrosis, similar to those found in lichen planopilaris.
April 2023 in “Journal of Investigative Dermatology”
This study reports distinctive clinical, trichoscopic, and histopathological features of fibrosing alopecia in a pattern distribution among Chinese patients, suggesting possible racial differences compared to previous studies primarily involving Caucasians.
29 citations
,
July 2008 in “Journal of Cutaneous Pathology”
This study found that follicular streamers are mostly present in non-scarring alopecia cases, and tracking their location can improve diagnosis accuracy.
October 2014 in “Journal of the Portuguese Society of Dermatology and Venereology”
This paper presents a therapeutic approach with excellent results in a case of lichen planopilaris overlapping with dermatomyositis and scleroderma, although broader applicability is not discussed.
13 citations
,
August 1995 in “Australasian Journal of Dermatology”
This study found that hair canal and follicle diameters, outer root sheath area, and terminal-to-vellus hair ratios were significantly reduced in androgenetic alopecia patients compared to normal controls.
PP405 is ineffective for miniaturized, fibrosedhairfollicles in androgenetic alopecia. AMP303 may activate hairfollicle stem cells, but minoxidil and finasteride are still the main treatments.
Hairfollicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hairfollicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.
Age affects hair loss severity and treatment effectiveness, with younger individuals often experiencing more aggressive loss but potentially better regrowth due to less follicle miniaturization. Treatments like finasteride and minoxidil are commonly used, and early intervention is crucial for better outcomes.
Pelage is developing a topical hairfollicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.